One04 Therapeutics launches on encouraging CPV-104 Phase 1 interim results and plans to expand clinical development to include kidney diseases and dry AMDFreiburg, Germany, September 15, 2026 – One04 Therapeutics GmbH & Co. KG today announced its launch as a clinical-stage biopharmaceutical company with encouraging Phase 1 results for CPV-104, a first-in-class, full-length recombinant human Factor H candidate with disease-modifying potential across a broad range of complement-mediated diseases.
